Darlene Dobkowski, MA

An expert discussed how oncology nurses can help social workers seek available financial resources for patients by opening the conversation about any needs to be addressed.

Erdafitinib was approved for the treatment of adults with locally advanced or metastatic urothelial carcinoma, which amends a previously approved indication of the drug.

Speaking with patients with cancer about financial toxicity, including available resources to help them pay for treatment and other necessities, can become a collaborative effort within an institution.

Pembrolizumab plus chemoradiotherapy has been approved by the FDA for the treatment of patients with FIGO 2014 stage III to IVA cervical cancer.

After 3 years, ruxolitinib provided improved control for steroid refractory or dependent chronic graft-versus-host disease when compared with best available treatment.

One patient speaks about her myeloproliferative neoplasm symptoms and how nurses have helped her along the way—despite issues with staffing shortages and high nursing turnover rates.

Compared with CAR T-cell therapy, autologous hematopoietic cell transplantation lowered relapse and progression rates in relapsed large B-cell lymphoma.

Overall, 65.9% of patients who received the combination of pelabresib and ruxolitinib demonstrated a 35% or greater reduction in spleen volume by week 24.

Remote patient monitoring following CAR T-cell therapy may reduce costs while allowing nurses to maintain a close eye on patient parameters, although more research is needed to refine the process of alerting virtual nurses of potential issues.

Tarlatamab induced a 40% objective response rate among patients with pretreated small cell lung cancer—including many patients who had already received 3 lines of therapy.

The FDA has approved encorafenib plus binimetinib to treat adults with metastatic non-small cell lung cancer with a BRAF V600E mutation.

Tetyana Furmanets, CRNP, MSN, discusses the tools she uses to help patients navigate myeloproliferative neoplasm symptom management.

Patients with pancreatic and gastric cancers residing in states with expanded Medicaid had improved survival rates.

Tisagenlecleucel evoked similar efficacy and a preferrable safety profile in children and adults with B-ALL being treated in a real-world analysis, compared with the clinical trial ELIANA.

Findings presented at the 2021 San Antonio Breast Cancer Symposium suggest that Certain adverse effects associated with olaparib were minimal and resolved with appropriate management in patients with breast cancer.

Characteristics such as low positive PD-L1 expression and rare high positive staining were identified in both patients with VHL-mutated and VHL wild type clear cell renal cell carcinoma.

Due to the favorable efficacy and safety profiles of daratumumab plus lenalidomide and dexamethasone, researchers speculate that the combination may become the new standard of care in multiple myeloma treatment.

Patients with myeloma and a negative MRD may be at a reduced risk of mortality and other progression-free survival events.

Amanpour, who is CNN's chief international anchor, announced her diagnosis live on-air, while advocating for cancer screening, too.

CURE Media Group also recognized Jennifer E. Giovanni, PhD, MSN, MPH, RN, as winner of the Finest Hour Award, which highlights the dedi- cation and selflessness exhibited in frontline workers during the COVID-19 pandemic.

States without Medicaid expansion tended to have poorer cancer outcomes than states with higher income limits on eligibility, according to recent research.

A clinic for patients with a history of cancer led by an advanced practice nurse and a dietician may empower patients to improve their lifestyles through diet and exercise, especially since it may have an impact on their outcomes and future risk for diseases.

Although survivors and patients with lung cancer felt that they were involved in the treatment decision-making process, nearly half of them reported that they knew what their treatment options were before making a decision, according to results from a study presented at the 2020 World Conference on Lung Cancer Singapore.

Findings from an analysis determined that stage 4 gastrointestinal stromal tumors were rare and led to hepatic metastases, although overall survival was up to 51% at 5 years.